Marinomed Biotech (MARI) Stock Overview

A biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. More details

MARI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health0/6
Dividends0/6

MARI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Marinomed Biotech AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Marinomed Biotech
Historical stock prices
Current Share Price€19.00
52 Week High€19.80
52 Week Low€2.00
Beta-0.079
1 Month Change2.70%
3 Month Change53.85%
1 Year Change57.02%
3 Year Change-70.03%
5 Year Change-81.55%
Change since IPO-75.00%

Recent News & Updates

Recent updates

A Look At The Fair Value Of Marinomed Biotech AG (VIE:MARI)

May 25
A Look At The Fair Value Of Marinomed Biotech AG (VIE:MARI)

Marinomed Biotech AG (VIE:MARI) Could Be Riskier Than It Looks

Feb 03
Marinomed Biotech AG (VIE:MARI) Could Be Riskier Than It Looks

Marinomed Biotech AG (VIE:MARI) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Apr 22
Marinomed Biotech AG (VIE:MARI) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Marinomed Biotech AG's (VIE:MARI) Analyst Just Slashed This Year's Estimates

Sep 22
Marinomed Biotech AG's (VIE:MARI) Analyst Just Slashed This Year's Estimates

Shareholder Returns

MARIAT PharmaceuticalsAT Market
7D-2.3%-0.03%1.2%
1Y57.0%-21.3%16.6%

Return vs Industry: MARI exceeded the Austrian Pharmaceuticals industry which returned -21.3% over the past year.

Return vs Market: MARI exceeded the Austrian Market which returned 16.6% over the past year.

Price Volatility

Is MARI's price volatile compared to industry and market?
MARI volatility
MARI Average Weekly Movement6.1%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement4.0%
10% most volatile stocks in AT Market5.9%
10% least volatile stocks in AT Market2.6%

Stable Share Price: MARI's share price has been volatile over the past 3 months compared to the Austrian market.

Volatility Over Time: MARI's weekly volatility has decreased from 15% to 6% over the past year, but is still higher than 75% of Austrian stocks.

About the Company

FoundedEmployeesCEOWebsite
200639Andreas Grassauerwww.marinomed.com

Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company’s products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; and Inhaleen for viral infection of the upper and lower respiratory tract.

Marinomed Biotech AG Fundamentals Summary

How do Marinomed Biotech's earnings and revenue compare to its market cap?
MARI fundamental statistics
Market cap€33.79m
Earnings (TTM)-€15.42m
Revenue (TTM)€4.79m
7.0x
P/S Ratio
-2.2x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MARI income statement (TTM)
Revenue€4.79m
Cost of Revenue€3.77m
Gross Profit€1.03m
Other Expenses€16.44m
Earnings-€15.42m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Sep 17, 2025

Earnings per share (EPS)-8.67
Gross Margin21.40%
Net Profit Margin-321.66%
Debt/Equity Ratio-111.9%

How did MARI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/14 03:50
End of Day Share Price 2025/07/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Marinomed Biotech AG is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vladimira UrbankovaErste Group Bank AG
Alexander RihaneFirst Berlin Equity Research GmbH
Matthias GreiffenbergerGBC AG